Quarterly ResultApr 30, 2026, 08:29 AM
NCEL 2025 Net Loss $8.3M; Accelerates Type 1 Diabetes Program
AI Summary
NewcelX Ltd. reported a net loss of $8.3 million for the period ended December 31, 2025, with cash and cash equivalents at $2.2 million. The company is accelerating the development of NCEL-101, its Type 1 Diabetes treatment, in collaboration with Eledon Pharmaceuticals, aiming for IND-enabling milestones in 2026. NewcelX also strengthened its balance sheet by closing a financing of up to $3.4 million and appointing Julien Boisdron, MD, to its Scientific Advisory Board. The company expects 2026 to be a year of significantly accelerated execution, including expanding strategic collaborations and pursuing additional financing.
Key Highlights
- Accelerated development of NCEL-101 for Type 1 Diabetes with Eledon Pharmaceuticals.
- Secured up to $3.4M in financing, including $1.35M cash and $2.0M potential from warrants.
- Maintains access to a $25M Equity Line of Credit.
- Appointed Julien Boisdron, MD, to Scientific Advisory Board.
- Reported 2025 net loss of $8.3 million.
- Cash and cash equivalents were $2.2 million as of December 31, 2025.
- Basic and diluted loss per share was $(2.16) for 2025.
- Net cash used in operating activities was $2.8 million in 2025.